Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Common Equity (2019 - 2025)

Historic Common Equity for Bolt Biotherapeutics (BOLT) over the last 7 years, with Q3 2025 value amounting to $32.1 million.

  • Bolt Biotherapeutics' Common Equity fell 5543.45% to $32.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.1 million, marking a year-over-year decrease of 5543.45%. This contributed to the annual value of $57.2 million for FY2024, which is 4926.6% down from last year.
  • As of Q3 2025, Bolt Biotherapeutics' Common Equity stood at $32.1 million, which was down 5543.45% from $38.8 million recorded in Q2 2025.
  • Over the past 5 years, Bolt Biotherapeutics' Common Equity peaked at $303.2 million during Q1 2021, and registered a low of $32.1 million during Q3 2025.
  • Moreover, its 5-year median value for Common Equity was $142.1 million (2023), whereas its average is $152.5 million.
  • As far as peak fluctuations go, Bolt Biotherapeutics' Common Equity surged by 65924.02% in 2021, and later plummeted by 5543.45% in 2025.
  • Quarter analysis of 5 years shows Bolt Biotherapeutics' Common Equity stood at $250.1 million in 2021, then plummeted by 31.43% to $171.5 million in 2022, then plummeted by 34.26% to $112.7 million in 2023, then tumbled by 49.27% to $57.2 million in 2024, then crashed by 43.88% to $32.1 million in 2025.
  • Its Common Equity stands at $32.1 million for Q3 2025, versus $38.8 million for Q2 2025 and $46.8 million for Q1 2025.